CD274 and neoplasm: However, the overall response rates for solid tumors are relatively low (less than 30%),[2] most likely due to the significant upregulation of endogenous PDL1 mRNA expression, which induces the intracellular PDL1 to return back to the surface of tumor cells, to maintain a homeostasis state and mediate immune resistance.[3] Thus, it may not be sufficient for targeting a single signaling pathway to attain robust anti‐tumor immunity and substantial therapeutic benefits.